Emerging data on patients who have had a drug-eluting stent (DES) procedure demonstrate the importance of patient adherence to dual anti-platelet therapy in reducing the risk of stent thrombosis.

A developing consensus recommends that physicians be part of a broad effort to ensure that patients are well informed and properly compliant post procedure.*

The Stentplus™ Patient Success Program is the first program of its kind designed to help the cardiology team meet this challenge in continuing care. The Stentplus™ Program provides tools to help your drug-eluting stent patients—regardless of stent brand—stay on the dual anti-platelet therapy you prescribe.

Stentplus.com explains the need for compliance and how the Stentplus™ Program will help you and your patients meet this challenge.

ACC/AHA/SCAI guidelines state "...clopidogrel should ideally be continued up to 12 months in all [drug-eluting stents] stented patients who are not at high risk of bleeding." For more information about ACC/AHA/SCAI guidelines, click here.

• Program Materials and Services
  The tools to enhance patient knowledge about the importance of continuing dual anti-platelet therapy
• Financial Assistance Resources
  Helps patients identify prescription assistance programs for which they may qualify

* The American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association (with representation from the American College of Physicians).